Compound Radar

Integra LifeSciences Holdings Corporation (IART) Stock Analysis

United States · Healthcare / Medical Devices

Price $16.26
Market cap $1.26B
Next earnings Oct 29, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 30
  • Profitability 50
  • Business Quality 75
  • Balance Sheet 30
  • Cash Flow 50

Why this rating?

Health 45/100 — Speculative

Strongest Business Quality 75/100
Softest Balance Sheet 30/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Integra LifeSciences Holdings Corporation (IART) is a Medical Devices company in the Healthcare sector. Compound Radar rates Integra LifeSciences Holdings Corporation 45/100 (Speculative) due to high business quality, steady revenue growth, and elevated leverage.

Investment profile

  • Quality High
  • Growth Moderate
  • Balance Sheet Stretched
  • Valuation Attractive

Financial highlights

Valuation

  • Forward P/E 6.23
  • PEG 0.67
  • EV/Revenue 1.87

Profitability

  • Revenue Growth 0.8%
  • Gross Margin 56.9%
  • Operating Margin 9.6%
  • Net Margin -0.4%
  • ROE -0.7%

Financial strength

  • Cash $274.08M
  • Debt $2.05B
  • Net Cash $-1.78B
  • Free Cash Flow $-45.25M
  • Current Ratio 3.6

Similar companies

Peers in Medical Devices, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Medical Devices →

FAQ

How Compound Radar scores and tracks Integra LifeSciences Holdings Corporation (IART).

View Methodology & FAQ →